HTFL · Insider Trading
Heartflow, Inc. Common Stock
Every open-market purchase and sale reported by HTFL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-10 | Marie L. Jones | Chief Accounting Officer | MIXED | +227 | −$14.10K |
| 2026-11-10 | John C.M. Farquhar | Chief Executive Officer | MIXED | −31,031 | −$2.54M |
| 2026-11-10 | Vikram Verghese | Chief Financial Officer | MIXED | −5,596 | −$295.92K |
| 2026-11-10 | Campbell Rogers | Chief Medical Officer | F | −2,270 | −$118.95K |
| 2026-10-26 | Campbell Rogers | Chief Medical Officer | MIXED | −6,503 | −$1.20M |
| 2026-10-14 | John C.M. Farquhar | Chief Executive Officer | Sell | −38,900 | −$1.93M |
| 2026-09-21 | Campbell Rogers | Chief Medical Officer | MIXED | −6,503 | −$882.46K |
| 2026-09-18 | Vikram Verghese | Chief Financial Officer | Sell | −24,345 | −$1.23M |
| 2026-09-15 | Vikram Verghese | Chief Financial Officer | Sell | −34,975 | −$1.75M |
| 2026-09-14 | John C.M. Farquhar | Chief Executive Officer | Sell | −38,900 | −$1.82M |
| 2026-09-10 | Vikram Verghese | Chief Financial Officer | Sell | −6,640 | −$332.21K |
| 2026-09-04 | Vikram Verghese | Chief Financial Officer | Sell | −33,416 | −$1.67M |
| 2026-08-25 | John C.M. Farquhar | Chief Executive Officer | Sell | −27,230 | −$1.36M |
| 2026-08-20 | John C.M. Farquhar | Chief Executive Officer | Sell | −32,676 | −$1.47M |
| 2026-08-19 | Campbell Rogers | Chief Medical Officer | MIXED | — | −$204.94K |
| 2026-08-18 | John C.M. Farquhar | Chief Executive Officer | Sell | −15,560 | −$607.77K |
| 2026-08-12 | John C.M. Farquhar | Chief Executive Officer | Sell | −22,562 | −$638.73K |
| 2026-08-10 | Vikram Verghese | Chief Financial Officer | MIXED | −1,339 | −$44.59K |
| 2026-08-10 | John C.M. Farquhar | Chief Executive Officer | F | −7,751 | −$213.85K |
| 2026-08-10 | Marie L. Jones | Chief Accounting Officer | MIXED | +1,093 | +$11.25K |
| 2026-08-10 | Campbell Rogers | Chief Medical Officer | F | −2,272 | −$62.81K |
| 2026-07-31 | John C.M. Farquhar | Chief Executive Officer | M | +31,220 | +$158.01K |
| 2026-07-28 | Jeffrey C Lightcap | Director | M | +47,420 | +$900.98K |
| 2026-07-28 | Vikram Verghese | Chief Financial Officer | M | +22,522 | +$50.00K |
| 2026-07-24 | Timothy C Barabe | Director | M | +3,710 | +$70.49K |
| 2026-07-23 | Vikram Verghese | Chief Financial Officer | M | +22,522 | +$50.00K |
| 2026-07-20 | Timothy C Barabe | Director | M | +5,000 | +$95.00K |
| 2026-07-17 | Campbell Rogers | Chief Medical Officer | MIXED | — | −$61.95K |
| 2026-07-13 | John C.M. Farquhar | Chief Executive Officer | Sell | −22,562 | −$626.10K |
| 2026-07-10 | William C Weldon | Director | M | +51,369 | +$427.90K |
| 2026-06-26 | John C.M. Farquhar | Chief Executive Officer | Sell | −38,900 | −$1.36M |
| 2026-06-18 | Timothy C Barabe | Director | A | +16,075 deriv. | — |
| 2026-06-18 | Julie A Cullivan | Director | A | +16,075 deriv. | — |
| 2026-06-18 | Casey M Tansey | Director | A | +16,075 deriv. | — |
| 2026-06-18 | Jeffrey C Lightcap | Director | A | +16,075 deriv. | — |
| 2026-06-18 | Wayne Joseph Riley | Director | A | +16,075 deriv. | — |
| 2026-06-18 | William C Weldon | Director | A | +16,075 deriv. | — |
| 2026-06-17 | Campbell Rogers | Chief Medical Officer | M | +10,000 | +$22.20K |
| 2026-06-12 | John C.M. Farquhar | Chief Executive Officer | Sell | −22,562 | −$643.02K |
| 2026-05-20 | Campbell Rogers | Chief Medical Officer | MIXED | — | −$86.11K |
| 2026-05-13 | John C.M. Farquhar | Chief Executive Officer | Sell | −22,562 | −$657.01K |
| 2026-05-08 | Marie L. Jones | Chief Accounting Officer | F | −567 | −$17.15K |
| 2026-05-08 | John C.M. Farquhar | Chief Executive Officer | F | −7,204 | −$217.62K |
| 2026-05-08 | Campbell Rogers | Chief Medical Officer | F | −2,271 | −$68.59K |
| 2026-05-08 | Vikram Verghese | Chief Financial Officer | F | −2,009 | −$60.71K |
| 2026-04-14 | John C.M. Farquhar | Chief Executive Officer | Sell | −22,562 | −$602.86K |
| 2026-04-03 | Campbell Rogers | Chief Medical Officer | MIXED | +2,484 | −$1.44M |
| 2026-03-26 | HealthCor Partners Management LP | Director | J | −4,615,542 | — |
| 2026-03-26 | Jeffrey C Lightcap | Director | J | +206,261 | — |
| 2026-03-23 | Campbell Rogers | Chief Medical Officer | MIXED | +2,484 | −$1.51M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bain Capital Life Sciences Fund III, L.P. | 10%+ Owner | 12,448,158 | $717.64M |
| Bain Capital Life Sciences Investors, LLC | 10%+ Owner | 10,448,158 | $602.34M |
| Casey M Tansey | Director | 3,089,206 | $178.09M |
| Jeffrey C Lightcap | Director | 1,542,620 | $88.93M |
| HCPCIV 1, LLC | 10%+ Owner | 833,075 | $48.03M |
| John C.M. Farquhar | Chief Executive Officer | 283,014 | $16.32M |
| William C Weldon | Director | 209,685 | $12.09M |
| Timothy C Barabe | Director | 188,231 | $10.85M |
| Vikram Verghese | Chief Financial Officer | 171,949 | $9.91M |
| Campbell Rogers | Chief Medical Officer | 148,140 | $8.54M |
| Marie L. Jones | Chief Accounting Officer | 32,258 | $1.86M |
| Julie A Cullivan | Director | 27,291 | $1.57M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HTFL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.